The New Zealand Myocarditis study is STILL a work in progress. We have written about it several times previously. It was initially due to be published in early 2023, and then the researchers were very close to being able to share the results in March and then again in June 2023. In August 2023 it was undergoing a robust review process. Although it was then due to be published in the first quarter 2024, the researchers were still working through the analysis of the participant responses in Jan 2024. Now in June 2024 this is the current state of play:
Unfortunately, we do not have an update at this time. There has been little progress
made in the sign out process due to end of fiscal year constraints and other urgent priorities. These have resulted in a delay of the approval and publication. We understand how important the results of this study are to the participants and are urgently working towards publishing the report as soon as possible. The final report will be available here when it is published: COVID-19 vaccine side effects and
reactions | Health Information and Services.
COVID-19 vaccine: Myocarditis and pericarditis study.
Will the New Zealand Myocarditis Study ever see the light of day?
Curiously, the few sympathetic politicians there are have not followed this up. This is disrespectful to all those New Zealanders who were damaged by a “vanishingly rare” adverse event of the safe and effective genetic injection and who agreed to share their time and health information with the researchers.
The email address for contacting the myocarditis study group is c19myostudy@health.govt.nz for those wanting to follow up the results. It will be monitored from 15 Jan 2024.
Further Reading on the NZ Myocarditis Study:
- Delayed Results on a 2022 Myocarditis Study – April 8, 2023
- Update on Delayed Myocarditis Study Results – September 3, 2023
- Myocarditis Study Disappears as Profitable Product Receives Full Approval – January 10, 2024
The article was originally published by NZDSOS.
